MAP2K2

(redirected from MEK2)

MAP2K2

A gene on chromosome 19p13.3 that encodes mitogen-activated protein kinase kinase 2, which catalyses the simultaneous phosphorylation of a threonine and a tyrosine residue in MAP kinases; it also activates the ERK1 and ERK2 MAP kinases.

Molecular pathology
Defects of MAP2K2 cause cardiofaciocutaneous syndrome.
References in periodicals archive ?
Similar binding affinities of AKT, MEK1, MEK2, STAT3 and mTOR were calculated for honokiol (range from -9.
org/pdb); EGFR (PDB ID:), ART (PDB ID: 3E87), mTOR (PDP ID: 4JSP), MEK1 and MEK2 (PDB IDs: and respectively) and homology-modelled structure of human STAT3 created by us from murine crystal structure (PDB ID:) were set as the rigid receptor molecule.
NASDAQ: ARRY) and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2.
MEK inhibitor-induced receptor tyrosine kinase (RTK) stimulation overcame MEK2 inhibition, reactivating ERK and resulting in drug resistance.
Implication of MEK1 and MEK2 in the establishment of the blood-placenta barrier during placentogenesis in mouse.
Trametinib (GSK1120212) is also an investigational, orally bioavailable inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2.
RAF phosphorylates and activates both MEK1 and MEK2 on two distinct serine residues (Crews et al.
MEK162, a small molecule selective inhibitor of the kinases MEK1 and MEK2, showed clinical activity and good tolerability in this patient population.
NCCN recently received $4 million in the form of two research grants from GlaxoSmithKline to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor, both promising therapies in the treatment of advanced melanoma.